Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	5/29/1947
Gender:	Female
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

Borrelia burgdorferi (Lyme Disease) Reflexive Panel (CSF)

ARUP test code 2007335

Borrelia burgdorferi Abs, ELISA, CSF

2.27 LIV H (Ref Interval: <=0.99)

Borrelia burgdorferi Antibodies, IgG and IgM by Immunoblot to follow.

INTERPRETIVE INFORMATION: Borrelia burgdorferi Abs, ELISA, CSF

0.99 LIV or less:	Negative - Antibody to B. burgdorferi not detected.
1.00 - 1.20 LIV	Equivocal - Repeat testing in 10-14 days may be helpful.
1.21 LIV or greater:	Positive - Probable presence of antibody to B. burgdorferi detected.

The detection of antibodies to B. burgdorferi in cerebrospinal fluid may indicate central nervous system infection. However, consideration must be given to possible contamination by blood or transfer of serum antibodies across the blood-brain barrier.

Current CDC recommendations for the serologic diagnosis of Lyme disease are to screen with a polyvalent ELISA test and confirm equivocal and positive results with immunoblot. Both IgM and IgG immunoblots should be performed on samples less than 4 weeks after appearance of erythema migrans. Only IgG immunoblot should be performed on samples greater than 4 weeks after the disease onset. IgM immunoblot in the chronic stage is not recommended and does not aid in the diagnosis of neuroborreliosis or chronic Lyme disease. Please submit requests for appropriate immunoblot testing within 10 days.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Borrelia burgdorferi Antibody, IgG by Immunoblot (CSF)

ARUP test code 0055259

Borrelia burgdorferi Ab, IgG, IB (CSF)

Positive * (Ref Interval: Negative)

Band(s) present: 93, 66, 45, 41, 39, 28, 18 kDa

H=High, L=Low, *=Abnormal, C=Critical

INTERPRETIVE INFORMATION: Borrelia burgdorferi Ab, IgG, IB (CSF)

For this assay, a positive result is reported when any 5 or more of the following 10 bands are present: 18, 23, 28, 30, 39, 41, 45, 58, 66, or 93 kDa. All other banding patterns are reported as negative.

The detection of antibodies to Borrelia burgdorferi in cerebrospinal fluid may indicate central nervous system infection. However, consideration must be given to possible contamination by blood or transfer of serum antibodies across the blood-brain barrier.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Borrelia burgdorferi Antibody, IgM by Immunoblot (CSF)

ARUP test code 0055258

Borrelia burgdorferi Ab, IgM, IB (CSF)	Negative	(Ref Interval: Negative)

Band(s) present: NONE
(Insufficient number of bands for positive result)
Current CDC recommendations for the serologic diagnosis of Lyme disease are to screen with a polyvalent EIA test and confirm equivocal and positive with Immunoblot. Both IgM and IgG Immunoblots should be performed on samples less than 4 weeks after appearance of erythema migrans. Only IgG Immunoblot should be performed on samples greater than 4 weeks after disease onset. IgM Immunoblot in the chronic stage is not recommended and does not aid in the diagnosis of neuroborreliosis or chronic Lyme disease. Please submit requests for appropriate Immunoblot testing within 10 days.

INTERPRETIVE INFORMATION: Borrelia burgdorferi Ab, IgM, IB (CSF)

For this assay, a positive result is reported when any 2 or more of the following bands are present: 23, 39, 41 kDa. All other banding paterns are reported as negative.

The detection of antibodies to Borrelia burgdorferi in cerebrospinal fluid may indicate central nervous system infection. However, consideration must be given to possible contamination by blood or transfer of serum antibodies across the blood-brain barrier.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Borrelia burgdorferi Abs, ELISA, CSF	21-139-143803	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Borrelia burgdorferi Ab, IgG, IB (CSF)	21-139-143803	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Borrelia burgdorferi Ab, IgM, IB (CSF)	21-139-143803	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical